# Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

> **NCT03645928** · PHASE2 · TERMINATED · sponsor: **Iovance Biotherapeutics, Inc.** · enrollment: 225 (actual)

## Conditions studied

- Metastatic Melanoma
- Squamous Cell Carcinoma of the Head and Neck
- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Lifileucel
- **BIOLOGICAL:** LN-145
- **DRUG:** Pembrolizumab
- **BIOLOGICAL:** LN-145-S1
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **DRUG:** Nivolumab-relatlimab
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Nab paclitaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT03645928
- **Lead sponsor:** Iovance Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-07
- **Primary completion:** 2026-02-20
- **Final completion:** 2026-02-20
- **Target enrollment:** 225 (ACTUAL)
- **Why stopped:** After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints.
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03645928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03645928, "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03645928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*